London, United Kingdom, January, 2013 –(PR.com)– TechNavio launched its report, Global Non-small Cell Lung Cancer Drugs Market 2012-2016, based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the significant trends impacting this market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said: “Personalized medicines have the ability to provide customized treatment to patients. Customized treatment is based on the genetic profile and the medical profile of the patient. Biomarkers help in predicting the patient response to a particular drug. By making use of biomarkers, personalized medicines help identify the patient population set that is more likely to respond to a particular drug therapy. Personalized medicines are increasingly being used in targeted cancer therapies. The major market players are increasingly investing in targeted agents and the development of personalized therapies. In the future, as personalized medicines become reality, the conventional approaches will automatically become obsolete.”
According to the report, one of the key drivers is the increase in the number of people suffering from cancer. Across the globe, the prevalence of cancer is growing at a significant pace. Increased urbanization coupled with sedentary lifestyles has led to an increase in the number of people suffering from cancer. The prevalence of cancer is not only increasing in developed countries, but also in low- and middle-income countries, particularly in India, China, and Japan.
Further, the report reveals that one of the key market challenges is the increasing use of complementary and alternative medicine (CAM).
The key vendors dominating this market space are AstraZeneca plc., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and Sanofi S.A.
The other vendors mentioned in the report are Bristol-Myers Squibb Co., GlaxoSmithKline Plc., Novartis AG, and OSI Pharmaceuticals Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit www.technavio.com/content/global-non-small-cell-lung-cancer-drugs-market-2012-2016
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?